- Hemoragicko-traumatický šok po teroristickém útoku - léčba v Polní nemocnici Armády České republiky ROLE II+, Kábul2008 | Publikace bez příslušnosti k fakultě
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer2023 | Publikace bez příslušnosti k fakultě
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study2016 | 1. lékařská fakulta
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial2017 | Lékařská fakulta v Hradci Králové
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial2019 | Lékařská fakulta v Hradci Králové, 3. lékařská fakulta
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial2022 | 1. lékařská fakulta
- Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study2023 | 1. lékařská fakulta
- Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study2022 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
